Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management

Cancers, Journal Year: 2023, Volume and Issue: 15(2), P. 485 - 485

Published: Jan. 12, 2023

Obesity or excess body fat is a major global health challenge that has not only been associated with diabetes mellitus and cardiovascular disease but also risk factor for the development of mortality related to subgroup cancer. This review focuses on epidemiology, relationship between obesity recurrence cancer management obesity.

Language: Английский

---

Healthy Lifestyle and Cancer Risk: Modifiable Risk Factors to Prevent Cancer

Nutrients, Journal Year: 2024, Volume and Issue: 16(6), P. 800 - 800

Published: March 11, 2024

Cancer has become a serious problem worldwide, as it represents the main cause of death, and its incidence increased over years. A potential strategy to counter growing spread various forms cancer is adoption prevention strategies, in particular, use healthy lifestyles, such maintaining weight, following diet; being physically active; avoiding smoking, alcohol consumption, sun exposure; vitamin D supplementation. These modifiable risk factors are associated with this disease, contributing development, progression, severity. This review evaluates relationship between potentially overall specifically breast, colorectal, prostate cancer, highlights updated recommendations on prevention. The results numerous clinical epidemiological studies clearly show influence lifestyles development cancer. An incorrect diet, composed mainly saturated fats processed products, resulting body combined physical inactivity, induced an increase all three types under study. Given importance adopting correct prevent global institutions should develop strategies environments that encourage individuals adopt regular behaviors.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Journal of clinical lipidology, Journal Year: 2024, Volume and Issue: 18(3), P. e320 - e350

Published: April 24, 2024

BACKGROUNDThis joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk.METHODSThis is based upon scientific evidence, perspectives authors, peer OMA NLA leadership.RESULTSAmong individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles.CONCLUSIONSObesity increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. Among patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD. This risk. leadership. particles.

Language: Английский

---

Obesity, dyslipidemia, and cardiovascular disease: A joint expert review from the Obesity Medicine Association and the National Lipid Association 2024

Obesity Pillars, Journal Year: 2024, Volume and Issue: 10, P. 100108 - 100108

Published: March 12, 2024

This joint expert review by the Obesity Medicine Association (OMA) and National Lipid (NLA) provides clinicians an overview of pathophysiologic clinical considerations regarding obesity, dyslipidemia, cardiovascular disease (CVD) risk. is based upon scientific evidence, perspectives authors, peer OMA NLA leadership. Among individuals with adipose tissue may store over 50% total body free cholesterol. Triglycerides represent up to 99% lipid species in tissue. The potential for expansion accounts greatest weight variance among most individuals, percent fat ranging from less than 5% 60%. While population studies suggest a modest increase blood low-density lipoprotein cholesterol (LDL-C) levels excess adiposity, adiposopathic dyslipidemia pattern often described adiposity includes elevated triglycerides, reduced high density (HDL-C), increased non-HDL-C, apolipoprotein B, LDL particle concentration, small, dense particles. increases CVD risk, at least partially due promotion adiposopathic, atherogenic profile. also worsens other cardiometabolic risk factors. patients interventions that reduce improve outcomes are generally associated improved levels. Given improvement LDL-C reduction overweight or early treat both (LDL-C and/or non-HDL-C) priorities reducing CVD.

Language: Английский

---

Gut Microbiome and Its Impact on Obesity and Obesity-Related Disorders

Current Gastroenterology Reports, Journal Year: 2022, Volume and Issue: 25(2), P. 31 - 44

Published: Dec. 5, 2022

Language: Английский

---

Obesity, diabetes mellitus, and cardiometabolic risk: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2023

Obesity Pillars, Journal Year: 2023, Volume and Issue: 5, P. 100056 - 100056

Published: Jan. 28, 2023

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of type 2 diabetes mellitus (T2DM), obesity-related cardiometabolic risk factor.

Language: Английский

---

A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2023, Volume and Issue: 24(4), P. 611 - 631

Published: March 31, 2023

Language: Английский

---

Lycopene: A Potent Antioxidant with Multiple Health Benefits

Journal of Nutrition and Metabolism, Journal Year: 2024, Volume and Issue: 2024(1)

Published: Jan. 1, 2024

Lycopene is a naturally occurring carotenoid predominantly found in tomatoes and tomato‐based products. Like other phytochemicals, it exhibits health beneficial biological activities that can be exploited when used as dietary supplement. In vitro vivo , lycopene has been demonstrated to mitigate oxidative stress‐induced metabolic dysfunctions diseases including inflammation, obesity, diabetes mellitus. shown alleviate affect the bone, eye, kidney, liver, lungs, heart, nervous system. This review presents state of art regarding lycopene’s benefits its potential applications system delivery. Furthermore, protective effects against toxins, safety use, possible toxicity are explored.

Language: Английский

---

Harnessing Nanotechnology for Idarubicin Delivery in Cancer Therapy: Current Approaches and Future Perspectives

BioNanoScience, Journal Year: 2024, Volume and Issue: 14(4), P. 4108 - 4130

Published: April 11, 2024

Language: Английский

---

Thirty Obesity Myths, Misunderstandings, and/or Oversimplifications: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

Obesity Pillars, Journal Year: 2022, Volume and Issue: 3, P. 100034 - 100034

Published: Aug. 10, 2022

This Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) is intended to provide clinicians an overview of 30 common obesity myths, misunderstandings, and/or oversimplifications. The scientific support for this CPS based upon published citations, clinical perspectives OMA authors, and peer review by the leadership. discusses oversimplifications, utilizing referenced publications such as integrative use other CPSs help explain applicable physiology/pathophysiology. on oversimplifications one a series designed assist in care patients with disease obesity. Knowledge underlying science may medicine clinician improve

Language: Английский

---